Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Emgality ® ▼ (galcanezumab)
Emgality®▼ (galcanezumab): Storage and Stability
Store the medicine in a refrigerator (2 °C to 8 °C). Do not freeze. Store in the original package in order to protect from light.
Emgality may be stored unrefrigerated for single period up to 7 days when stored at temperatures up to 30 °C. If the device is stored at a higher temperature or for a longer period it must be discarded.1
Once the device has been intentionally stored at room temperature, it should not be returned to the refrigerator and should be discarded, if unused, within 7 days.2
The medicine should not be used if the device is damaged, or the medicine is cloudy or has particles in it.1
The medicine should not be used after the expiry date which is stated on the label and on the carton after “EXP.”. The expiry date refers to the last day of that month.1
The medicine should be kept out of the sight and reach of children.1
Product in the Possession of the Healthcare Provider
The 7-day room temperature storage is reserved for patient/caregiver use only.2
Healthcare facilities (e.g. doctor’s office, pharmacy, etc.) and wholesalers or distribution centers cannot use any part of the patient’s 7-day room temperature storage time.2
If Emgality is exposed to temperatures outside the recommended storage and handling range, Lilly personnel can perform a product quality assessment to determine potential impact to the product. This product quality assessment is not intended to replace the recommended storage or handling conditions for the product.2
Lilly can only assess the potential impact of the temperature exposure to the product on a case-by-case basis and after the event has occurred. You must be able to provide the batch number, the amount of time, what temperatures and what type of light (if applicable) the Emgality was exposed to outside of the recommended storage and handling conditions. The product quality assessment must occur after the temperature or light exposure has ended and the products have been returned to the recommended storage conditions.2
3. Emgality [instructions for use]. Eli Lilly Nederland B.V., The Netherlands.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: February 18, 2019